Glancy Prongay & Murray LLP Announces Investigation on Behalf of Reliq Health Technologies Inc. Investors

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Reliq Health Technologies Inc. (“Reliq” or the “Company”) (TSXV: RHT, OTCQB: RQHTF) investors concerning the Company and its officers’ possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

The investigation concerns whether Reliq misled investors regarding future revenues and customer reimbursements. On October 16, 2018, Reliq announces that it has decided to restate certain financial information reported for the quarter ended March 31, 2018. On this news, shares of Reliq fell significantly during intraday trading, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased Reliq Therapeutics securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005787/en/